Firm
Firms in Canada explain how they’ve adapted to a rule change in 2017 that has made advocacy skills more important in pharma disputes
Leaders at some IP businesses are looking to consolidate the fragmented market and, considering the benefits, their rivals may want to follow suit
Counsel at three US firms explain how they are expanding their UPC teams or if they are looking to partner with European firms
Lucy Wheatley, partner at McGuireWoods, discusses the challenges of explaining trademarks to a jury and reveals a logistical hurdle she had to navigate
Sponsored
Sponsored
-
Sponsored by InspicosThe European Patent Office (EPO)’s requirement for the description of a patent to confirm the claims at the final stage of grant or opposition proceedings is coming under attack, as Jakob Pade Frederiksen of Inspicos explains -
Sponsored by Tilleke & GibbinsSher Hann Chua of Tilleke & Gibbins Thailand discusses the latest revision to Thailand’s guidelines on franchising, focusing on the changes to the first-refusal requirement
-
Sponsored by FB RicePaul Whenman of FB Rice reviews recent cases concerning patent term extension (PTE) for human pharmaceutical products in Australia
-
Sponsored by Tilleke & GibbinsA recent case highlights the tension between trademarks and right of publicity in Vietnam. Famous individuals should develop a protection strategy, argue Linh Thi Mai Nguyen and Chi Lan Dang of Tilleke & Gibbins Vietnam
-
Sponsored by Saint Island International Patent & Law OfficesMany software-related patent applications are rejected on the ground of non-obviousness. Yen-Bin Gu of Saint Island International Patent & Law Offices provides some tips for applicants
-
Sponsored by MaiwaldHeike Röder-Hitschke of Maiwald discusses a significant European Court of Justice (CJEU) ruling, and how it will affect future practice in preliminary injunction proceedings
